UCB's Global Corporate Website

Welcome to UCB in the United States

Newsroom

Find U.S. news and updates from UCB, a global biopharmaceutical company focused on creating value for people living with severe diseases, such as epilepsy, Parkinson’s disease, psoriasis, osteoporosis, myasthenia gravis, rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and more.

Spotlight Story

No results

UCB U.S. News

Sep 30, 2024

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab…

Sep 27, 2024

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe…

Sep 25, 2024

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis…

Twitter Feed

For More Information

Speaker Requests

Connect with Us on Social

@UCBUSA Twitter

UCB USA YouTube